Phase II Optimization, Open-Label Clinical Trial of Zalypsis® (PM00104) in Relapsed/Refractory Multiple Myeloma Patients

被引：0

作者：

Ocio, Enrique M. ^{[1
]}

De La Rubia, Javier ^{[2
]}

Oriol-Rocafiguera, Albert ^{[3
]}

Blade, Joan ^{[4
]}

Rodriguez, Jose ^{[5
]}

Coronado, Cinthya ^{[5
]}

Martin Sanchez, Jesus ^{[6
]}

Isabel Teruel, Ana ^{[7
]}

Hernandez-Maraver, Dolores ^{[8
]}

Prosper, Felipe ^{[9
]}

San-Miguel, Jesus. F.

机构：

[1] Hosp Univ Salamanca, Inst Invest Biomed Salamanca IBSAL, Salamanca, Spain

[2] Hosp Univ La Fe, Valencia, Spain

[3] Hosp Badalona Germans Trias & Pujol, Barcelona, Spain

[4] Hosp Clin Barcelona, Barcelona, Spain

[5] PharmaMar, Madrid, Spain

[6] Hosp Univ Virgen del Rocio, Seville, Spain

[7] Hosp Clin Univ Valencia, Valencia, Spain

[8] Hosp La Paz, Madrid, Spain

[9] Univ Navarra Clin, Pamplona, Spain

来源：

BLOOD | 2012年 / 120卷 / 21期

关键词：

D O I：

10.1182/blood.V120.21.4041.4041

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

4041

引用

页数：2

共 50 条

[41] A phase II trial of imatinib in patients with refractory/relapsed myeloma
Dispenzieri, A
Gertz, MA
Lacy, MQ
Geyer, SM
Greipp, PR
Rajkumar, SV
Kimlinger, T
Lust, JA
Fonseca, R
Allred, J
Witzig, TE
LEUKEMIA & LYMPHOMA, 2006, 47 (01) : 39 - 42
[42] Phase II open-label study of recombinant circularly permuted TRAIL as a single-agent treatment for relapsed or refractory multiple myeloma
Leng, Yun
Qiu, Lugui
Hou, Jian
Zhao, Yaozhong
Zhang, Xuejun
Yang, Shifang
Xi, Hao
Huang, Zhongxia
Pan, Ling
Chen, Wenming
CHINESE JOURNAL OF CANCER, 2016, 35 : 86
[43] A multicenter phase II trial of thalidomide and celecoxib for patients with relapsed and refractory multiple myeloma
Prince, HM
Mileshkin, L
Roberts, A
Ganju, V
Underhill, C
Catalano, J
Bell, R
Seymour, JF
Westerman, D
Simmons, PJ
Lillie, K
Milner, AD
Di Iulio, J
Zeldis, JB
Ramsay, R
CLINICAL CANCER RESEARCH, 2005, 11 (15) : 5504 - 5514
[44] Phase II trial of nab-paclitaxel in patients with relapsed or refractory multiple myeloma
Jain, Tania
Dueck, Amylou C.
Kosiorek, Heidi E.
Ginos, Brenda F.
Mayo, Angela
Reeder, Craig B.
Chesi, Marta
Mikhael, Joseph
Stewart, A. Keith
Bergsagel, P. Leif
Fonseca, Rafael
AMERICAN JOURNAL OF HEMATOLOGY, 2016, 91 (12) : E504 - E505
[45] A phase II trial with gemcitabine and paclitaxel for the treatment of refractory and relapsed multiple myeloma patients
Gazitt, Yair
Shaughnessy, Paul
Rothenberg, Mace L.
ONCOLOGY REPORTS, 2006, 16 (04) : 877 - 884
[46] Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial
Lonial, Sagar
Weiss, Brendan M.
Usmani, Saad Z.
Singhal, Seema
Chari, Ajai
Bahlis, Nizar J.
Belch, Andrew
Krishnan, Amrita
Vescio, Robert A.
Victoria Mateos, Maria
Mazumder, Amitabha
Orlowski, Robert Z.
Sutherland, Heather J.
Blade, Joan
Scott, Emma C.
Oriol, Albert
Berdeja, Jesus
Gharibo, Mecide
Stevens, Don A.
LeBlanc, Richard
Sebag, Michael
Callander, Natalie
Jakubowiak, Andrzej
White, Darrell
de la Rubia, Javier
Richardson, Paul G.
Lisby, Steen
Feng, Huaibao
Uhlar, Clarissa M.
Khan, Imran
Ahmadi, Tahamtan
Voorhees, Peter M.
LANCET, 2016, 387 (10027): : 1551 - 1560
[47] A phase 1 clinical trial of oral eltanexor in patients with relapsed or refractory multiple myeloma
Cornell, Robert Frank
Baz, Rachid
Richter, Joshua R.
Rossi, Adriana
Vogl, Dan T.
Chen, Christine
Shustik, Chaim
Alvarez, Mariano J.
Shen, Yao
Unger, T. J.
Ben-Shahar, Osnat
Wang, Hongwei
Baloglu, Erkan
Senapedis, William
Ma, Xiwen
Landesman, Yosef
Bai, Xiang
Bader, Justin
Xu, Hongmei
Marshall, Tracey
Chang, Hua
Walker, Christopher J.
Shah, Jatin
Shacham, Sharon
Kauffman, Michael G.
Hofmeister, Craig C.
AMERICAN JOURNAL OF HEMATOLOGY, 2022, 97 (02) : E54 - E58
[48] An Open-Label Phase I Study of the Safety and Efficacy of RAD001 in Combination with Lenalidomide in the Treatment of Patients with Relapsed and Relapsed/Refractory Multiple Myeloma
Raje, Noopur
Richardson, Paul
Hari, Parameswaran N.
Mahindra, Anuj
Kaster, Sarah
Connolly, Christine
Rivera, Linda
Chetri, Gaurav
Dean, Sarah
Jacobs, Paulette
Saad, Ayman
Laubach, Jacob
Ghobrial, Irene M.
Schlossman, Robert L.
Adams, Jennifer
Makrides, Wendy
Weller, Edie
Munshi, Nikhil
Anderson, Kenneth C.
BLOOD, 2009, 114 (22) : 1483 - 1483
[49] A Multicenter, Open Label Phase I/II Study of Carfilzomib, Pomalidomide and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma (MM) Patients
Bringhen, Sara
Magarotto, Valeria
Liberati, Anna Marina
Belotti, Angelo
Larocca, Alessandra
Gilestro, Milena
Bonello, Francesca
Gaidano, Gianluca
Bertazzoni, Paola
Stocchi, Raffaella
Ribolla, Rossella
Di Sano, Chiara
Patriarca, Francesca
Passera, Roberto
De Paoli, Lorenzo
Oliva, Stefania
Cafro, Anna Maria
Sonneveld, Pieter
Palumbo, Antonio
Boccadoro, Mario
BLOOD, 2016, 128 (22)
[50] Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial
Mateos, Maria-Victoria
Nahi, Hareth
Legiec, Wojciech
Grosicki, Sebastian
Vorobyev, Vladimir
Spicka, Ivan
Hungria, Vania
Korenkova, Sibirina
Bahlis, Nizar
Flogegard, Max
Blade, Joan
Moreau, Philippe
Kaiser, Martin
Iida, Shinsuke
Laubach, Jacob
Magen, Hila
Cavo, Michele
Hulin, Cyrille
White, Darrell
De Stefano, Valerio
Clemens, Pamela L.
Masterson, Tara
Lantz, Kristen
O'Rourke, Lisa
Heuck, Christoph
Qin, Xiang
Parasrampuria, Dolly A.
Yuan, Zhilong
Xu, Steven
Qi, Ming
Usmani, Saad Z.
LANCET HAEMATOLOGY, 2020, 7 (05): : E370 - E380

← 1 2 3 4 5 →